Recently, an increasing number of systemic therapies with life extending capacity have become available in metastatic castration resistant prostate cancer (mCRPC) i.e. Abiraterone acetate, Enzalutamide, Sipuleucel-T, Docetaxel, Cabazitaxel and Radium-223. More compounds are currently being evaluated in promising pivotal trials (e.g. Tasquinimod, ARN-509, ODM-201, and more). Limitations of the currently available biomarkers make treatment decisions challenging. Considering the ever increasing complexity of treatment algorithms in mCRPC the current demand of research is to find and characterize biomarkers with prognostic, predictive and surrogate quality, allowing for information on clinically meaningful outcomes and on which therapy to offer patients in different and complex scenarios.
INTRODUCTION
After decades of futile efforts to develop life-prolonging therapies in metastatic castration resistant prostate cancer (mCRPC), remarkable progress has been achieved during the past ten years. Several compounds with different methods of action were approved. In the pre-chemotherapy setting, the antihormonal agents, Abiraterone and Enzalutamide [1, 2] and immunotherapy with Sipuleucel-T [3] are currently approved for men with asymptomatic or oligosymptomatic mCRPC. Docetaxel and Cabazitaxel are registered cytotoxic chemotherapy agents with life prolonging potential [4] [5] [6] . In the setting after Docetaxel chemotherapy, Abiraterone and Enzalutamide have been approved as well [7, 8] . Finally, the alpha-emitter Radium-223 has been registered for the treatment of men with symptomatic bone metastatic CRPC without indication for chemotherapy and excluded visceral metastasis [9] . The hazard ratios (HR), improvement of overall survival (OS), progression free survival (PFS) and objective response in these trials are depicted in Table 1 . Several promising phase-III registration trials are ongoing which will, if successful, broaden the armamentarium *Address correspondence to this author at the Department of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany; Tel: +49-(0)-251-83-44600; Fax: +49-(0)-251-83-48310; E-mail: martin.boegemann@ukmuenster.de against mCRPC even more. Amongst others, promising compounds in advanced stages of development are Tasquinimod [10] or Galeterone [11] .
Recently, a trend has set in of moving the therapeutic compounds to earlier phases of the course of prostate cancer (PCa). The rationale for this is to hit the disease before mechanisms of resistance have developed and to treat patients in a better general condition to enable longer drug exposure. This concept has first been underlined by Sweeney et al. showing that androgen deprivation therapy (ADT) plus Docetaxel improved OS by 17 months compared to ADT alone in men with high-volume metastatic castration sensible prostate cancer [12] . This will lead to a shift of chemotherapy to the early first-line treatment of metastatic castration sensible prostate cancer. Furthermore, there are ongoing and planned trials combining approved drugs with little toxicity and trials on sequencing available drugs to achieve maximal survival benefit.
Sequencing therapies for mCRPC within the different scenarios of application (1st and 2nd line chemotherapy, preand post chemotherapy) is already demanding today. The future of CRPC treatment described above will be complicated further and will increase the demand for treatment algorithms even more. Several questions arise: Which is the best sequence of compounds in the individual patient? When does a treatment need to be stopped and when should it be continued? This is especially important in asymptomatic or oligosymptomatic patients in whom the lack of change in symptoms poses challenges for the treating physician regarding reasonable decision-making, especially with the limitations of present biomarkers.
The absence of reliable and easily available biomarkers is a major challenge for everybody involved in CRPCtreatment. Clinicians repeatedly have to make calculated treatment decisions depending on scarce data on sequence of therapies and on how to deal with a drug in equivocal clinical situations. This leads to a large number of patients being treated with a suboptimal drug in the first place and to a suboptimal treatment duration (too long or short). In general, "non-toxic" drugs tend to be given for too long. As a result of this, subclinical progression of the disease can occur rendering subsequent therapies like taxane-based chemotherapy impossible and thus, detain the patient for a further line of therapy. "Toxic" compounds tend to be used more cautiously.
Especially in bone metastatic CRPC (80-90% of mCRPC-patients), the so-called "bone-flare" is a common phenomenon within efficacious therapy. Here, hitherto occult bone metastases can become visible on imaging mimicking progression. This leads to a marked number of misinterpretations as progressive disease when in reality the disease is in remission or stable. This difficulty holds especially true in asymptomatic or oligosymptomatic patients [13] . So up to now, it is the standard of care to repeat imaging two to three months later to confirm true progression or remission/stable disease. In case of bone flare biomarkers may be very helpful to facilitate treatment decisions.
POTENTIAL OF BIOMARKERS IN CRPC
A biomarker is defined as a medical sign that objectively gives information about the state of the patient that can be measured accurately and is reproducible [14] . The measured response may be functional, physiological, biochemical at the cellular level, or a molecular interaction [15] . The main challenge in a vastly growing field is to determine the degree of correlation between a biomarker and a relevant clinical endpoint [16] . Examples for good clinical endpoints are survival outcomes like PFS or OS that are the present gold standards for pivotal trials. Other noteworthy endpoints are quality of life-parameters.
An ideal biomarker in general and specifically in CRPC, would therefore be one that is preferably measured prior to the start of therapy and informs the physician on whether a drug is likely to be efficacious concerning a clinically meaningful endpoint (predictive biomarker). In addition, a biomarker which is being used for monitoring during therapy, should be informative for the treating physician on whether to continue or to stop a given therapy at a very early point of therapy even when clinical signs or imaging information Furthermore, today's registrations trials still try to meet the gold standard of significantly improved overall survival. With an increasing number of life extending follow-uptherapies after having used an investigational compound, this goal becomes ever harder to accomplish. A good surrogate biomarker for OS, when being accepted by the FDA for this prediction, could therefore be a solution for this dilemma giving early information of survival and not being compromised by follow-up therapies allowing for registration of promising drugs, which otherwise might not produce significant survival advantages. At the same time, it would speed up the duration of registration trials by far, since the endpoint is reached earlier than the death of disease of a determined percentage of study subjects. This review aims to provide an overview about the available data and the possible future regarding predictive, prognostic and surrogate biomarkers in mCRPC.
The discussed biomarkers and their relevance in CRPC are also depicted in Tables 2 and 3: PROSTATE SPECIFIC ANTIGEN AND DERIVATES
The most renowned biomarker in prostate cancer in general is prostate specific antigen (PSA). While having its limitations in predicting prostate cancer prior to prostate biopsy in the range of 2-10 ng/ml and being very critically discussed as a prostate cancer screening marker [17, 18] , it is broadly accepted as a marker in recurrent disease after definitive therapy. It is also commonly accepted as a response indicator within initial androgen deprivation therapy. Dynamic PSA-changes like PSA-doubling time or PSA-velocity are correlated with diagnosis of PCa at biopsy [19] . Both can be used to predict PCa recurrence and development of metastases [20] [21] [22] . PSA reflects the burden of disease in CRPC [23] . As a part of nomograms, PSA can be used to predict OS [24, 25] . For CRPC-patients prior to the start of Docetaxel chemotherapy, several studies showed that PSA-doubling time is prognostic for OS [26, 27] . However, several problems in the CRPC-setting make interpretation of PSA-changes demanding. One challenge is the different way PSA changes under different systemic treatments. For instance, Sipuleucel-T improves OS without having impact on PSA, while decline of PSA correlates with the outcome of Docetaxel chemotherapy [3] . Baseline PSA, in contrast to baseline CTCs and LDH-levels, was no surrogate for OS under Abiraterone therapy [28] . PSAdoubling time can change spontaneously without an impact of systemic therapy, thus making interpretation problematic [29] . Docetaxel chemotherapy was recently shown to possibly directly influence androgen receptor dynamics [30] . This may relativize the data of improved OS with declining PSA under Docetaxel. At the same time, PSA can rise under antitumoral therapy for three or sometimes six months before potentially declining [31] . This PSA-flare can occur due to treatment response or even represent tumor necrosis with consequent circulatory PSA-release and might therefore harbor favorable prognosis [32] . Especially in asymptomatic or oligosymptomatic patients, this phenomenon can either prove true or just go along with subclinical progression that can easily be missed and therefore unnecessarily delay subsequent therapy. The "prostate cancer working group 2" (PCWG2) therefore recommends not to stop an individual therapy only because of early rising PSA, especially within clinical trials. However, the group advises to document the efficacy of an individual therapy by determining the relative amount of patients with a PSA decline of ≥50% later in therapy (i.e. after 12 weeks) [33] . Percentage of free PSA (%fPSA) improves the specificity of prostate cancer screening compared to total PSA [34] . Another PSA subfraction, a truncated form of precursor PSA ([-2]proPSA) and its derivates like %[-2]proPSA and the so called "Prostate Health Index" (PHI) = ([-2]proPSA / free PSA) x √PSA) improve the prediction of PCa at initial and repeated prostate biopsy compared to tPSA and even outperform %fPSA [35] [36] [37] [38] [39] [40] [41] [42] [43] . These interesting markers however have not been tested within the setting of CRPC, yet.
LACTATE DEHYDROGENASE
The Lactate Dehydrogenase (LDH) is an unspecific biomarker in many tumor-types. In general, elevated or inclining LDH reflects higher tumor burden and/or high proliferation activity [44] . In some tumors, it has an impact on therapy decisions as in risk stratifications of germ cell cancers leading to different therapy regimens when inclined above certain cut offs [45] . It plays a role in CRPC as well. In the COA-AA-301 registration trial of Abiraterone for the post chemotherapy setting, baseline-LDH > upper normal limit like the enumeration of circulating tumor cells (CTCs) was prognostic for OS [8] . Therefore, a combination of LDH and CTCs in a marker panel has been proposed. The normalization of a beforehand-elevated LDH or rising LDH under therapy might be predictive of response as well. LDH-level as marker of response within a given therapy with the compounds registered in the last 10 years has not been tested.
ALKALINE PHOSPHATASE
Alkaline Phosphatase (ALP) is an enzyme involved in bone turnover and therefore is an important biomarker in bone metastatic CRPC. It has been shown to be prognostic for response and OS in patients with mCRPC treated with Docetaxel and Radium-223 [33, 46, 47] . A model with the combination of ALP, hemoglobin and age was proposed to be used for the determination of the optimal number of cycles of Docetaxel [48] . Finally, ALP was found to be useful to differentiate PSA-flare from PSA-progression during early Docetaxel-chemotherapy [49] . Thus, serial measurements of ALP to discern dynamic changes may provide prognostic information within other modern therapies and could facilitate treatment decisions.
INFLAMMATION BIOMARKERS
Interleukin 8 (IL-8) is a mediator of inflammation and it is in addition involved in angiogenesis [50] , which makes it important for nutrition and tumor growth. Therefore, it may be tumor mass dependent. In a group of 122 men with hormone sensible PCa, elevated IL-8-levels measured two weeks after initiation of primary ADT were found to be predictive for OS and there was a trend towards prediction of shorter time to developing castration resistance [51] . It may be relevant for therapy monitoring in CRPC but has not been studied in this field, yet.
C-reactive protein (CRP) is an acute-phase-protein that besides inflammation reaction and necrosis seems to play a role in carcinogenesis [52] . In CRPC-patients treated with Docetaxel, Ito et al. found CRP-levels to be independently associated with longer OS [53] . Baseline CRP was found to be predictive for OS in several phase-II trials for CRPCpatients treated with Docetaxel, Calcitriol, Estramustine, Carboplatin, Imatinib, Zoledronic acid and Abarelix [54] . However, despite being interesting, the relevance of CRP for the drugs approved after 2004 has not been systematically tested, especially for therapy monitoring.
TMPRSS2-ERG (TRANSMEMBRANE PROTEASE, SERINE 2-ETS FUSION)
In 2005, gene members of the ETS-family (v-ets erythroblastosis virus E26 oncogene; ERG and ETS variant gene 1; ETV1) were found to be overexpressed in 57% of PCa. A fusion with the 5′ untranslated region of the androgenregulated gene Transmembrane Protease, Serine 2 (TMPRSS2) is the underlying cause of the overexpression [55] . This TMPRSS2-ERG rearrangement can be detected in voided urine and is thus easily available [56] . It is highly specific for PCa [57, 58] , but sensitivity is limited in a pre-prostate biopsy setting with only 37% [59] . This is of course irrelevant when PCa has already been detected but makes TMPRSS2-ERG-fusion interesting as a potential marker of response in PCa. Initial research in the field of CRPC was done by Danila et al. who studied TMPRSS2-ERG-fusion in CTCs as a pre-treatment biomarker of tumor sensitivity to Abiraterone [60] . In this study however, TMPRSS2-ERG status did not predict the decline of PSA or other clinical outcomes. The effect of Abiraterone on the rearrangement under therapy was not studied. In another study, TMPRSS2-ERG-RNAexpression was sequentially derived from the peripheral blood mononuclear cell fraction of CRPC-patients under chemotherapy with Docetaxel [61] . From baseline to weeks 9 and 27 and 2 months after the end of treatment, a median decrease of TMPRSS2-ERG-levels of 86% (95%CI: 60-100%) was detectable in 37% of patients. Taris et al. found that ERG-expression is associated with better outcomes in CRPC probably because of androgen receptor dependency of ERG-expression and thus better response to androgen suppression in these cancers [62] .
Micro-RNAs
Micro-RNAs (miRNAs) are short, non-coding RNAs with a length of about 20 nucleotides. They can interact with cellular mRNA and thus have an impact on apoptosis and cell cycle. miRNAs can be detected in most body fluids and are associated with the presence of cancer [63] . Since they can be found in blood or urine, they are available in a noninvasive manner and therefore represent an ideal biomarker option. The miRNAs miR-107 and miR-574-3p for example, were found in higher concentrations in urine of PCa-patients compared to healthy controls but were only assessed in a pre-biopsy setting [64] . A study by Kuner et al. focused on miRNAs in serum and plasma [65] . Here, miR-141 and miR-375 were found to be candidates as diagnostic and prognostic biomarkers. An elevation of miR-141 was correlated with metastatic PCa as compared with localized disease and miR-141, together with miR-375 were associated with higher Gleason score and the presence of lymph node metastases.
In a cell culture study on tissue derived miRNAs from bone metastases of 17 CRPC-patients, Sun et al. found that compared to normal prostate tissue and the tissue of localized PCa, up-regulation of miR221/-222 and downregulation of miR-23b/-27b were associated with the development of CRPC in 16/17 (90%) patients [66] . In localized, hormone sensitive PCa, miR221/-222 was found to be downregulated. Compared to healthy bone marrow, the expression rate of miR221/-222 was shown to be increased 2.4/4.6 fold (p=0.019/<0.001). The same group found that miR-221 promotes androgen independence by downregulation of HECTD2 and RAB1A [67] . Another miRNA overexpressed in CRPC and being regulated by androgens is miR-32 [68] .
The first miRNAs to be tested in CRPC in the context of a specific therapy are the miR-200 family-and miR-17 familymembers that were identified as independent predictors of OS when tested prior to Docetaxel chemotherapy or in early docetaxel therapy when combined with pre-chemotherapy hemoglobin levels and the presence of visceral metastasis in a marker model [69] . All of these results are promising and miRNAs might be usable as predictive, prognostic or surrogate biomarkers. But the findings are preliminary and need to be validated since all results were retrieved from small cohorts [70] . A problem with most miRNA is that they are altered only in small fractions of patients making them not ideal for use with all patients and therefore may impede future wide spread use. However, miR221/-222 seems to be a promising exception of this phenomenon.
EXOSOMES
Exosomes are small vesicles that are being secreted by different cell types including tumor cells and encase proteins and RNAs representing their origin [71] . Like miRNAs, they can be found in virtually all body fluids making them promising biomarkers. Potentially, the mRNA contained within exosomes is better preserved compared to the mRNA from whole cell isolates [72] . Information on the role of exosomes in PCa and CRPC is still scarce. In a proof of concept study, PCA3 and TMPRSS2-ERG-fusion could be isolated from urine in PCa patients [73] . Here, TMPRSS2-ERG was only detectable within exosomes of patients with high Gleason score and high PSA. This could, after further elaboration of the concept, represent an option of identifying patients at high risk for the development of CRPC. Mitchell et al. described a marked decrease of urinary exosome contents after ADT, which may indicate potential value as a therapy control marker [74] . Recently, a study on 23 CRPCpatients showed that the presence of plasma exosomal miR-1290 and mi-375 was significantly associated with poor overall survival [75] . However, the role of exosomes as predictive biomarkers in the context of a specific antitumoral therapy has not been examined, yet. Most data were established on very small cohorts. Further studies need to be done to define the role of exosomes for the management of PCa and CRPC. Improvement of practicability of detection of exosomes and its contents is warranted since with currently available assays, the detection is complex and time consuming.
CIRCULATING TUMOR CELLS (CTCs) AND SPLICE VARIANTS
Following vessel invasion, tumor cells can become CTCs. Technology to detect and count CTCs from peripheral blood is commercially available. De Bono et al. were the first to find a significant correlation between CTC-enumeration and OS in CRPC [32] . They described that <5 CTCs at baseline or a conversion from ≥ 5 CTCs to < 5 CTCs under therapy are strong surrogates for favorable prognosis and OS. CTCs proved to be an even stronger predictor for survival endpoints than PSA. These results were supported by the studies of Scher and Olmos [76, 77] . CTC alterations often occur prior to PSA-changes and no flares have been reported. This makes CTC enumeration over time very promising for therapy control when PSA-or bone-flare make decisions difficult [28] . Within the COA-AA-301 registration trial of Abiraterone in the post-chemotherapy setting, baseline CTC-and LDH-levels were found to be predictive for improved OS while baseline PSA was not associated with survival outcomes [78] .
The CTC enumeration is currently being scrutinized in several large phase-III trials with the purpose of having CTCs ultimately accepted by the FDA as a validated surrogate parameter for OS within the registration trials [79] . This could dramatically speed up registration processes and lower thresholds of conducting trials, which would otherwise not be done because of long follow-up phases and extremely high costs. However, with currently available assays, the sensitivity is fairly low and hence the amount of false negative findings is relatively high. In a PSA-range of 0-20 ng/ml, CTCs are rarely detectable at all [28, 32] . At the same time, equipment and kits for testing CTCs are not broadly available. The price for a single test is high, which makes sequential testing, as needed for decision-making within ongoing therapies, a high financial burden. Conclusively, CTCs are currently used rather in clinical trials than every day routine, but future development of point-of-care assays, broader availability and reduced price might change this eventually.
An advancement of pure counting of CTC-enumeration could be reached by molecular profiling of peripheral blood mononuclear cells. In 2011, a study on 41 CRPC-patients found that TMPRSS2-ERG-fusion could be detected in CTCs of 37% of patients prior to Abiraterone. However, a correlation between molecular findings and outcome of Abiraterone treatment could not be shown [60] . In another study, the same group described a marker-panel consisting of five mRNAs (KLK3, KLK2, HOXB13, GRHL2 and FOXA1) measured in whole blood samples of 97 CRPCpatients [80] . The hazard ratio for improved overall survival for the gene panel was 3.23 and 3.24 for CTC-enumeration measured with the CellSearch ® -system [80] . The combination of the 5-marker panel with CTC-counts of the CellSearch ® -system improved the prediction of survival compared to CTC-counts alone (hazard ratio = 4.34). The concordance probability estimate (CPE) was 0.752, representing a 75% concordance between the prognostic index and survival time.
Recently, the presence of AR-splice variant 7 (ARv7) derived from CTCs was found to be highly predictive for treatment resistance and reduced progression-free survival prior to Abiraterone and Enzalutamide [81] . In the future, detection of ARv7 may be useable as a pre-treatment parameter. This may be particularly important in the setting after failure of initial Abiraterone or Enzalutamide treatment. Here the development of cross-resistance against Enzalutamide after Abiraterone or the other way around [82] [83] [84] [85] is a pressing problem. ARv7 detection prior to switch of therapy could magnificently help to avoid inefficacious treatment in the state of resistance. In contrast to ARv7, another splice variant (ARv567) may be used to predict response to taxane-based therapy. In a preclinical study on ARv567-expressing LuCap86.2 tumor xenografts, docetaxel was highly efficacious whereas ARv7-expressing LuCap23.1 xenografts displayed docetaxel resistance [86] . More splice variants are under investigation and those identified to date have to be tested and validated in surveyed clinical studies. Altogether, splice variants derived from CTCs may in future represent a practicable and valuable tool to predict response or resistance to diverse available therapies comparable to resistograms within antibiotic therapies of infections.
TISSUE MARKERS
Tissue markers in CRPC can be obtained from biopsy of metastases, from prostate biopsy specimens or from specimens of palliative resection of the prostate. Several markers have been tested in the setting of prostate biopsy prior to PCa diagnosis and in a situation of suspected recurrence of PCa after local therapy (Ki-67, PTEN, ECadherin, EZH2) [87] [88] [89] [90] . The Polaris ® test is a commercially available marker panel based on 34 cell cycle genes that combined into a score were validated as prognostic for disease progression pre and post prostatectomy [91, 92] . Dynamin 2 (Dyn2) is essential for intracellular vesicle formation and trafficking, cytokinesis and receptor endocytosis. It was found to be associated with poor prognosis when overexpressed in prostate tissue in CRPC [93] . If tests like these can be transferred into CRPC-setting, remains to be evaluated.
PD-1 AND PD-L1/2
Programmed death-ligands-1 and -2 (PD-L1/2) are the ligands of the PD-1-receptor. The PD-L/PD-1 complex transmits an inhibitory signal to CD8-positive cytotoxic Tlymphocytes [94] . In human cancers, the up-regulation of PD-L1 can enable the cancer cells to evade the immune system. This has been shown in several cancer entities and has recently led to the approval of the first PD-1-antibodies (Nivolumab/Pembrolizumab) for the treatment of metastatic malignant melanoma [95] . In a preclinical trial on Enzalutamide-sensible CRPC-patients (n=4) and Enzalutamideresistant patients (n=8), Bishop et al. showed that PD-L1/2-expression on the dendritic cells was significantly increased in the Enzalutamide-resistant patients [96] . However, in a study on 68 patients with various tumor types, the subgroup of only 4 patients with CRPC was shown to be with no detectable PD-L1/2 activity in tumor infiltrating immune cells [97] . The possible impact of PD-L1/2 or PD-1 as markers prior to potential PD-1-Antibody therapy is currently unclear and remains to be elucidated.
CANCER STEM CELLS
Cancer stem cells (CSCs) can promote continuous advancement of tumor growth. They can lead to self-renewal and lead to differentiation into different cell types. Recent data have supported the concept that tumor cells undergoing an epithelial-mesenchymal transition (EMT) could be precursors for metastatic cancer cells, or even metastatic CSCs [98] . Normal, non-cancer somatic stem cells are naturally resistant to chemotherapy. The reason for this is their expression of various membrane transporter molecules (for example as MDR-1) [99] . CSCs developing from normal stem cells could produce these efflux pumps as well, which may partly be the reason for their resistance against chemotherapeutical approaches [100] . Another reason for the impaired efficacy of chemotherapy against CSCs may be a much slower cell turnover compared to normal tumor cells with chemotherapy mainly only affecting rapidly replicating cells. The surviving CSCs can then give rise to new tumor cells and repopulate the tumor, causing a relapse. In CRPC, ADT may have added to these phenomena, promoting disease progression by increasing the castration-resistant stem cell pool and/or activating formerly quiescent stem cells to repopulate [101] . Currently, the most important biomarker to identify CSCs in PCa is CD44 + α2β1 high CD133 + [102] . Tumor cells that express these properties are AR-negative. The notch-and the hedgehog-signaling pathways play an important role in tumorigenesis, angiogenesis, EMTdriven metastasis and renewal of CSCs [103] [104] [105] . In order to eventually be able to cure metastatic PCa and CRPC, it will be necessary to eliminate these cells [106] . Therefore, identifying CSCs using CD44 + α2β1 high CD133 + and targeting relevant signaling pathways of prostate-CSCs may be an option to overcome drug resistance and to improve long-term therapy and survival. A first phase-II trial with GDC-0449 (a hedgehog inhibitor) in combination with compound E (a notch inhibitor) in patients with CRPC currently addresses this problem [107] .
GENOMIC ABERRATIONS IN CRPC
While sequencing of the first human genome within the human genome project has cost approximately $3 billion [108] , the price for sequencing has recently been rapidly declining and in April 2014, reached $4920 per genome [109] , which has therefore approached a price-region of routine cross section imaging. Within other tumor types, for example breast cancer, whole genome sequencing is a rapidly evolving field of research with clinical application being introduced. In CRPC however, evidence is still scarce. First insights were shown by Lin et al. who found that most DNA methylation changes occurred in the context of allele-specific methylation, suggesting that epigenetics of individuals is partly mediated by genetic differences. Additionally, they described a panel of 13 cytosine guanine dinucleotide islands with increased methylation associated with disease progression that were validated in tissues of 16 PCa-patients with limited disease and in 8 patients with CRPC [110] . In a pilot study of whole genome sequencing in plasma, tumor-associated copy number changes of the androgen receptor locus were observed in CRPC as to compared to castration sensitive PCa. The group could also reproduce TMPRSS2-ERG rearrangement. The results were obtained within 2 days, indicating that the method might serve as a liquid biopsy [111] . In another study on formalinefixed paraffine-embedded tissue samples of CRPC-patients, Menon et al. found that YWHAZ was significantly knockeddown and PTK2 was inhibited [112] . Finally, Sowalsky et al. recently described extensive unspliced mRNA (e.g. AR, KLK2, KLK3, STEAP2, CPSF6 and CDK19) in CRPC, suggesting that ineffective splicing in advanced PCa provides a selective advantage but may render tumors potentially vulnerable to agents that suppress rate-limiting steps in splicing [113] . These observations are hypothesis generating since they might be prognostic for outcomes. But none of these genomic aberrations have yet been tested in this context.
IMAGING BIOMARKERS
Prostate specific membrane antigen (PSMA)-derived imaging has increasing relevance for metastatic PCa and CRPC. Its over-expression on the prostate cancer cell surface correlates with the dedifferentiation of the cell and is thus increasingly prominent in CRPC [114] . PSMA-ligands can be used for PET-CT imaging to detect metastases and likewise PET-CT-imaging that can be used for assessment of treatment response by measuring standardized uptake values (SUV). This is especially interesting since PSMA-targeted therapy is being evaluated with promising preliminary results [115] . PSMA-SUVs could serve as a therapy control biomarker in this setting.
Another relevant imaging biomarker with potential impact could be the so-called bone scan index (BSI). It measures the tumor burden of the skeleton and expresses it as a percentage of the total skeletal mass [116, 117] . Recently, several trials showed promising results of changes in BSI as a prognostic tool of therapy monitoring in bone metastatic CRPC [118] [119] [120] . But here as well, much needs to be learnt and further evaluated before broad use can be suggested.
FUTURE BIOMARKERS IN CRPC
Different CRPC patients may present with very different problems caused by different course of disease within diverse therapies. The initiation of therapy is moved to everearlier time points. In these settings, the proportion of patients with no or very little clinical symptoms increases rapidly. Under a given therapy, an asymptomatic patient will not be able to report on change of symptoms. Without proper information by imaging or reliable biomarkers, the treating physician is currently challenged to decide whether to continue or discontinue the therapy. Another task is defining clinically relevant endpoints other than the nowadays-gold standard OS and PFS with approval of regulatory authorities. Validated surrogate biomarkers for OS that could help to shorten the duration of trials and lower the threshold for drug developers to start a trial are non-existent. Currently, the number of available follow-up therapies with life prolonging capability increasingly compromises survival data and has led to the denial of market approval of potentially helpful compounds that might have obtained an "easy" approval just several years ago. This was the case with of the once promising drug Orteronel [121] .
Promising steps forward are currently being made. Especially the progress of CTC-technology is flourishing fast. When today's problems with relatively low sensitivity are overcome facilitating availability for routine monitoring of CRPC, changes in CTC-enumeration might be very helpful in deciding if a given therapy will have to be discontinued or switched to another treatment. The predictive value of splicevariants like ARv7 derived from CTCs [81] , prior to modern antihormonal therapies, shows promising potential. It may eventually work as a liquid biopsy prior to the start of therapy when several therapies are available and like a resistogram help decide which therapy to choose. Another possible use might be in whole genome sequencing of CTCs. With a greater understanding of carcinogenesis of PCa on the genomic level, it might be possible to better define study populations and enhance individual therapy strategies. This practice is already being applied in other tumor entities, for example breast cancer. When being accepted by regulatory authorities as a surrogate for OS, favorable changes of CTC-enumeration might greatly speed up registration trials and enable fast-track trials with by far lower thresholds for developers to get over in order to get approval for a compound. Promising developments in basic research on CSCs, which are part of the reason for drug resistance and ultimately failure of virtually all therapy approaches in the metastatic setting in CRPC, give hope to eventually target this hard to treat tumor manifestation [107] . This and a much faster turnover of treatment paradigms, a combination of therapies, may ultimately lead to cure of PCa and maybe CPRC.
Imaging biomarkers are important in order to quantify response to treatment. Current imaging in CRPC and especially in bone metastatic CRPC has the problem of equivocal findings due to potential bone-flare. Some compounds like antihormonal drugs, have a relatively high potential of causing bone-flare [13] , others like Cabozantinib go along with a high percentage of loss of bone metabolism activity [122] . Current evaluation of bone scans is done semi-quantitatively. So, the bone scan index might be a valuable tool to quantify change of bone metastasis. Such tests would have to be validated for different treatment options with different effects on bone metastases. Whenever a bone-flare is likely, additional or different biomarkers are needed to differentiate between bone-flare harboring good prognosis and true progression of bone metastases. Here, PSMA-based imaging might be a promising option [114] . A transfer of the bone scan index-tool on PSMA-PET-Imaging could be a future approach to address this problem.
Biomarker driven therapy monitoring and up-front therapy decisions would help to decide if early treatment failure occurs. This could allow for timely changes of treatment regimens, reducing precious time on inefficacious medication in which disease progression could render the patient incapable of reaching the next line of therapy. Thus, unnecessary toxicity may be spared and the therapy most likely to be efficacious could be chosen for the given patient.
However, a biomarker has to meet several characteristics in order to be a good biomarker. It has to provide additional data allowing to make decisions on subgroups of patients characterized by established classification systems to allow for wide spread use. Biomarkers qualify to be good not only by p-value or HR but by resulting in alteration of disease management. Therefore, the goal of research for future biomarkers will have to be that they are easy to obtain, easy to interpret, leading to reliable yes-or no-decisions while being cost-effective in order to achieve wide spread use.
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